Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN versus GATIFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN versus GATIFLOXACIN.
FLOXIN vs GATIFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of bacterial DNA gyrase and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Gatifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
400 mg orally every 12 hours for 10-14 days; ophthalmic solution: 1-2 drops in affected eye(s) every 2-4 hours for 2 days, then 1-2 drops 4 times daily for 10 days; otic solution: 5-10 drops in affected ear(s) twice daily for 10-14 days.
400 mg orally or intravenously once daily
None Documented
None Documented
Terminal elimination half-life of 10-14 hours in patients with normal renal function; prolonged in renal impairment (up to 40-50 hours in severe cases).
Clinical Note
moderateGatifloxacin + Digoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGatifloxacin + Digitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGatifloxacin + Deslanoside
"Gatifloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGatifloxacin + Acetyldigitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life 7-14 hours (mean ~10 hours in healthy adults); prolonged in renal impairment (up to 40 hours with CrCl <30 mL/min)
Approximately 70-90% excreted unchanged in urine via glomerular filtration and tubular secretion; about 10-30% eliminated in feces via biliary excretion.
Primarily renal excretion (70-87% unchanged in urine) via glomerular filtration and tubular secretion; ~10% biliary/fecal
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic